[Pseudomyxoma peritonei--diagnosis and treatment]
Yukihide Kanemitsu1, Tomoyuki Kato, Takashi Hirai
1Department of Gastroenterological Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 11, 2003
Summary
Pseudomyxoma peritonei is a rare malignancy characterized by gelatinous fluid and mucinous implants in the abdomen. Current treatments focus on surgical debulking, but effective therapies remain limited, leading to a poor prognosis.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Context:
- Pseudomyxoma peritonei (PMP) is an uncommon condition involving gelatinous ascites and peritoneal mucinous implants.
- It originates from neoplastic mucus-secreting cells within the peritoneal cavity.
- Radiologic imaging aids in presurgical diagnosis.
Purpose:
- To define the characteristics of pseudomyxoma peritonei.
- To highlight diagnostic modalities.
- To discuss the prognostic implications and current therapeutic limitations.
Summary:
- PMP involves diffuse gelatinous fluid and mucinous implants on peritoneal surfaces.
- The condition is attributed to neoplastic mucus-secreting cells.
- Diagnosis is facilitated by advanced imaging techniques.
Impact:
- Pseudomyxoma peritonei presents a significant therapeutic challenge.
- Despite surgical removal of metastatic sites, prognosis remains poor.
- Further research into effective therapies beyond debulking surgery is crucial.
